Stage of desease is a main prognostic factor (PF) for resected NSCLC (Mountain 1986). However the variety of clinical behaviour and the contradictory results of adjuvant treatment let oncologists suppose other PF to be investigated Since 1st january 1998 until 31st dicember 1998, 33 sequential patients (pts) with stage I NSCLC were operated by General Surgery Department of University in San Giuseppe General Hospital in Milan. Since the patients were all stage I no adjuvant treatment was provided. 19 pts were operated with lobectomy (L) and 14 wedge resection (WR). The patients follow-up lasts from 1998 until 31 december 2001. All operated tumors were analized for c-erb-B2 expression (IHC determinated) quantified in 0 , 1+, 2+ ,3+. At the time being 7 pts operated with L and 4 with WR are death. 12 L and 10 WR are alive. Results: in death patiens (11 pts): 7 pt (63.6%) with 0 or 1 + c-erb-B2 expression and 4 pts (34.4%) with 2+ or 3+ c-erb-B2 expression; in live pts without relapse disease (17 pts): 15 pts (88%) with 0 or 1+ c-erb-B2 expression and 2 pts (12% ) with 2+ or 3+ c-erb-B2 expression; in live pts with relapse disease (5 pts): 5 pts (100%) with 0 or 1+ c-erb-B2 expression; in all live pts (22 pts): 20 pts (91%) with 0 or 1+ c-erb-B2 expression and 2 pts (9%) with 2+ or 3+ expression. c-erb-B2(0-1+) c-erb-B2level(2-3+) death patients 7 (63.6%) 4 (34.4%) live patients (no relapse) 15 (88%) 2 (12%) live patients (with relapse) 5 (100%) 0 live patients (no relapse + relapse) 20 (91%) 2 (9%) The percentage of death pts to 2+ or 3+ c-erb-B2 expression is 3 times superior to the percentage of live pts (no relapse) to 2+ or 3+ c-erb-B2 expression, this difference with at 4 times if compare death pts to all live pts (Cox test p= 0.002). The expression of c-erb-B2 seems in this preliminary report to be an indipendent prognostic factor in stage I radically operated NSCLC. Our study in still ongoing. F23 A NEW SCHEDULING OF DAY 1 AND 8 EVERY THREE WEEKS
F22 C-ERB-B2: a new prognostic factor in NSCLC? Preliminary report of our experience / G. Roviaro, M. Maciocco, P. Belloni, A. Salomoni, S. Bosari, M. Clerici. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 13:3 supplemento(2002 Oct), pp. 84-84. ((Intervento presentato al 4. convegno 4th Nation Congress of Medical Oncology tenutosi a Torino nel 2002 [10.1093/annonc/mdf706].
F22 C-ERB-B2: a new prognostic factor in NSCLC? Preliminary report of our experience
G. RoviaroPrimo
;M. MacioccoSecondo
;S. BosariPenultimo
;M. ClericiUltimo
2002
Abstract
Stage of desease is a main prognostic factor (PF) for resected NSCLC (Mountain 1986). However the variety of clinical behaviour and the contradictory results of adjuvant treatment let oncologists suppose other PF to be investigated Since 1st january 1998 until 31st dicember 1998, 33 sequential patients (pts) with stage I NSCLC were operated by General Surgery Department of University in San Giuseppe General Hospital in Milan. Since the patients were all stage I no adjuvant treatment was provided. 19 pts were operated with lobectomy (L) and 14 wedge resection (WR). The patients follow-up lasts from 1998 until 31 december 2001. All operated tumors were analized for c-erb-B2 expression (IHC determinated) quantified in 0 , 1+, 2+ ,3+. At the time being 7 pts operated with L and 4 with WR are death. 12 L and 10 WR are alive. Results: in death patiens (11 pts): 7 pt (63.6%) with 0 or 1 + c-erb-B2 expression and 4 pts (34.4%) with 2+ or 3+ c-erb-B2 expression; in live pts without relapse disease (17 pts): 15 pts (88%) with 0 or 1+ c-erb-B2 expression and 2 pts (12% ) with 2+ or 3+ c-erb-B2 expression; in live pts with relapse disease (5 pts): 5 pts (100%) with 0 or 1+ c-erb-B2 expression; in all live pts (22 pts): 20 pts (91%) with 0 or 1+ c-erb-B2 expression and 2 pts (9%) with 2+ or 3+ expression. c-erb-B2(0-1+) c-erb-B2level(2-3+) death patients 7 (63.6%) 4 (34.4%) live patients (no relapse) 15 (88%) 2 (12%) live patients (with relapse) 5 (100%) 0 live patients (no relapse + relapse) 20 (91%) 2 (9%) The percentage of death pts to 2+ or 3+ c-erb-B2 expression is 3 times superior to the percentage of live pts (no relapse) to 2+ or 3+ c-erb-B2 expression, this difference with at 4 times if compare death pts to all live pts (Cox test p= 0.002). The expression of c-erb-B2 seems in this preliminary report to be an indipendent prognostic factor in stage I radically operated NSCLC. Our study in still ongoing. F23 A NEW SCHEDULING OF DAY 1 AND 8 EVERY THREE WEEKS
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
